Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictive Factors in Response to Inhaled Corticoids in Chronic Cough (FeNOTX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02715167
Recruitment Status : Unknown
Verified March 2016 by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.
Recruitment status was:  Not yet recruiting
First Posted : March 22, 2016
Last Update Posted : March 22, 2016
Sponsor:
Information provided by (Responsible Party):
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Brief Summary:
The hypothesis is that a high fractional exhaled nitric oxide can predict the response to inhaled corticoids in chronic cough.

Condition or disease Intervention/treatment Phase
Healthy Drug: Budesonide novolizer Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : March 2016
Estimated Primary Completion Date : April 2016
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough
Drug Information available for: Budesonide

Arm Intervention/treatment
Active Comparator: Group Budesonide
Inhaled corticoids
Drug: Budesonide novolizer
Placebo Comparator: Group Placebo
Placebo by inhalation
Drug: Placebo



Primary Outcome Measures :
  1. Leicester cough questionnaire [ Time Frame: 5 minutes ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • chronic cough

Exclusion Criteria:

  • active smoker
  • treated by corticoids during the previous month
  • use of angiotensin-converting-enzyme inhibitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02715167


Contacts
Layout table for location contacts
Contact: Rougui Ihsan, MD ihsan.rougui@hotmail.com

Sponsors and Collaborators
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Layout table for additonal information
Responsible Party: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ClinicalTrials.gov Identifier: NCT02715167    
Other Study ID Numbers: FeNOTX
First Posted: March 22, 2016    Key Record Dates
Last Update Posted: March 22, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Budesonide
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists